



Provider Update

February 8, 2022

DOH Deputy Secretary Laura C. Parajón, M.D., M.P.H
Infectious Disease Bureau Chief Dan Burke
NW Regional Health Officer Miranda Durham, M.D.

NM DOH Mission

To ensure health equity, we work with our partners to promote health and well-being, and improve health outcomes for all people in New Mexico.

Goals



We expand equitable access to services for all New Mexicans



We ensure safety in New Mexico healthcare environments



We improve health status for all New Mexicans



We support each other by promoting an environment of mutual respect, trust, open communication, and needed resources for staff to serve New Mexicans and to grow and reach their professional goals

COVID-19 Overview

Timeline:

Phases open through 1C2. Friday 3.19.21
Self scheduling for 75+ started 3.29.21
Self scheduling for booster doses started Thursday 4.1.21
All phases opened Monday 4.5.21
Self scheduling for those 60+ started Thursday 4.8.21
Janssen pause 4.12.21
DOH posts event code online - on purpose! For MEGA event 4.16.21
Self scheduling for 40+ starts Monday 4.19.21
Janssen pause lifted 4.23.21
Homebound button implemented 4.23.21
Self Scheduling for 16+ starts Monday 4.26.21
Age categories change on the dashboard 4.30.21 (now tracking 65+)
Vaccine Event Request Form implemented 5.10.21
Pfizer EUA expanded to include children aged 12 – 15. approved by ACIP Wednesday 5.12.21
Pfizer EUA extends vaccine storage from 5 days to 31 days in the refrigerator 5.20.21
NM announces state-wide vaccine lottery Tuesday 6.1.21
100\$ Incentive program for completed vaccine series Monday 6.14 – Thursday 6.17
NMAA allows vaccinated student athletes to compete without masks - Friday 6.17
60% fully vax declared Friday 6.18.21; reached 60% on dashboard Wednesday 6.23.21
Texas data added to NMSIIS Tuesday 6.29.21: 22,908 first doses, 12,104 second doses and 1,260 doses of J&J.
Dashboard changes to reporting 18+ and 12 – 17 in separate categories – Thursday 7.8.21
Second round of \$100 incentive announced Thursday, 7.29.21 and starts Monday 8.2.21
“Additional Dose” of mRNA vaccine approved for immunocompromised individuals by CDC – Friday 8.13.21
FDA grants full approval to Pfizer – Monday 8.23.21
August Incentive ends 8.31.21; opt in period ends 9.10.21
FDA VRBPAC authorizes Pfizer boosters for 65+ and high risk – Friday 9.17.21
CDC recommends single Pfizer booster at 6 months for certain high-risk populations 9.23.21
Dashboard metric changed from “age at time of vax” to “age now” and federal data added to race/ethnicity metric- 10.8.21
VRBPAC recommends Moderna and J&J boosters 10.14 - 10.15.21
CDC authorizes Moderna, J&J and Mix&Match boosters 10.22.21
FDA authorizes pediatric Pfizer vaccine (for ages 5 – 11) on 10.29.21
ACIP/CDC recommends pediatric Pfizer on 11.2.21
Boosters open to all 18+ in NM Friday 11.12.21
FDA/ACIP approve boosters for all 18+ 11.19.21

Timeline (cont.)

12.8.21	The F.D.A. authorizes AstraZeneca's <u>Evusheld</u> for emergency use
12.9.21	Pfizer boosters approved for 16 - 17 year olds
12.22.21	The F.D.A. authorizes Pfizer's Paxlovid for emergency use
12.23.21	The F.D.A. authorizes Merck's Molnupiravir for emergency use
1.3.22	The F.D.A. authorizes Pfizer vaccine boosters for everyone 12 and older and expanded 3rd dose for immune compromised individuals to include 5 - 11 year olds
1.3.22	The F.D.A changes booster dose time frame for Pfizer to "at least 5 months from primary series completion".
1.7.22	NM DOH recommends halting BAM/ETE and REGEN-COV due to high proportion of Omicron
1.7.22	The F.D.A changes booster dose time frame for Moderna to "at least 5 months from primary series completion".
1.31.22	Moderna's SpikeVax FDA approved
2.4.22	Moderna's SpikeVax endorsed by ACIP and CDC

COMMUNITY TRANSMISSION ACROSS THE USA



Community Transmission in US by County

	Total	Percent	% Change
High	3208	99.57%	-0.22%
Substantial	3	0.09%	0.03%
Moderate	0	0%	0%
Low	9	0.28%	0.12%

[How is community transmission calculated?](#)

[CDC COVID Data Tracker](#)

02/5/22

UNITED STATES LEVEL OF COMMUNITY TRANSMISSION
High

7 DAY CASE RATE PER 100,000
660.2

7 DAY PERCENT POSITIVITY
17.09%

CDC | Data as of: February 5, 2022 1:04 PM ET. Posted: February 5, 2022 3:05 PM ET

Cases

DAILY NEW CASES

● **117.0** PER 100K

INFECTION RATE

● **0.80**

POSITIVE TEST RATE

● **26.5%**

266

Extreme

75

Critical

25

High

10

Medium

1

Apr

Jun

Aug

Oct

Dec '20

Feb

Apr

Jun

Aug

Oct

Dec '21

Feb

117.0

Over the last week, New Mexico has averaged 2,452 new confirmed cases per day (**117.0** for every 100,000 residents). [About this data](#)

Share



Cases

DAILY NEW CASES


• **117.0** PER 100K

INFECTION RATE

• **0.80**

POSITIVE TEST RATE

• **26.5%**



On average, each person in New Mexico with COVID is infecting 0.80 other people. Because each person is infecting fewer than one other person, the total number of current cases in New Mexico is shrinking.

Share


About this data

Trends

METRIC
Deaths

PAST # OF DAYS
180

LOCATIONS
New Mexico



Share

Trends

METRIC

Hospitalizations




PAST # OF DAYS

180



LOCATIONS


New Mexico




Current COVID Hospitalizations — 7 Day Average

Share

Weekly COVID-10 Vaccines Administered in NM since 12/24/20




Continued gap for race/ethnicity for % completing vaccine series for 5 and older



Data are drawn from the New Mexico State Immunization Information System (NMSIIS) and Tiberius and include only residents of New Mexico. Last refresh on 2022-02-07

Vaccination Progress for Ages 5 - 11 and 12 - 15 (2nd dose)




Data are drawn from the New Mexico State Immunization Information System (NMSIIS) and Tiberius and include only residents of New Mexico.
Last refresh on 2022-02-08

Vaccine Watch List

- **Pfizer for 6mo - 4yo**
 - 3mcg dose; 3 dose primary series
 - 3rd dose is 8 weeks after dose 2
 - **VRBAC meeting Feb 15**
- **booster interval for immune compromised** - ACIP proposes shortening to 3 months after 3rd dose
- **mRNA dosing interval** - ACIP looking at 8 weeks between dose 1 and 2
- **Peds Pfizer for 5 - 11yo** - 3rd 10 mcg dose being studied
- **Omicron specific vaccine** - both Moderna and Pfizer studying Omicron-based vaccines
- **Novovax** - has WHO EUL - submitted request to FDA 1/31 for EUA

Building Nanoparticles

The researchers harvested the spike proteins from the moth cells and assembled them into nanoparticles. While the nanoparticles mimicked the molecular structure of the coronavirus, they could not replicate or cause Covid-19.



Vaccine Updates

Pfizer-BioNTech COVID-19 Vaccine Products

**PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/
CDC DOCUMENT – SHARED FOR JURISDICTIONAL PLANNING PURPOSES ONLY**

	Current Products		Future Product
Age Indications ^a	12 years and older	5 through 11 years	6 months through 4 years ^d
Vial Cap Color and Label with Color Border	GRAY 	ORANGE 	MAROON 
Preparation	Do Not Dilute	Dilute Before Use	Dilute Before Use
Amount of Diluent Needed per Vial ^b	Do Not Dilute	1.3 mL	2.2 mL
Dose Volume/Dose	0.3 mL/30 mcg	0.2 mL/10 mcg	0.2 mL/3 mcg
Doses per Vial	6 doses per vial	10 doses per vial (after dilution)	10 doses per vial (after dilution)
Storage Conditions			
ULT Freezer (-90°C to -60°C) ^c	9 months	9 months	9 months
Freezer (-25°C to -15°C)	DO NOT STORE	DO NOT STORE	DO NOT STORE
Refrigerator (2°C to 8°C)	10 weeks	10 weeks	10 weeks
Room Temperature (8°C to 25°C)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)
After First Puncture (2°C to 25°C)	Discard after 12 hours	Discard after 12 hours	Discard after 12 hours

^a Use the appropriate product based on the age of the recipient.

^b Diluent: Sterile 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

^c Regardless of storage condition, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons.

^d The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 6 months through 4 years old.

Pfizer **Maroon** Cap

- Please fill out the Pfizer PED survey as soon as possible:
<https://www.surveymonkey.com/r/CCRR9TM>
- Minimum order will be 100 doses.
- Order quantity sufficient for the first month (first and second doses)
- Immunization team will began placing orders this week for the first wave of the vaccine
 - 1st Wave: Preordering will occur from 9:00 AM on February 7 up to 9:00 AM on February 11.
Delivery on February 21st
 - 2nd wave: February 17th Noon-February 18th 9am. Delivery on February 22nd
 - Normal ordering through NMSIIS will start after February 25th or a week after CDC approves.

Holiday Alert

- **Presidents Day is Monday, February 21.**
- **If providers cannot receive vaccine on Presidents day, please notify Joelle by email to be included in the second order wave (delivery 2/22/22).**

Updates from the Immunization Program

- **J&J supply** - CDC will sunset J&J vaccine in the foreseeable future. If you need doses or have doses, email us at covid.vaccines@state.nm.us. Providers using J&J will need to start transitioning to an mRNA vaccine option.
- **Expiration Dates** - Please double check and update **Gray cap** and **Orange cap** Pfizer expiration dates in NMSIIS. If you are storing your vaccine in the refrigerator please adjust and reflect the 10 week expiration date in NMSIIS.
- **Immunization Gateway** - Nevada, Kentucky, Oklahoma
- **covid.vaccines@state.nm.us**

Immune compromised update

If an immunocompromised patient receives the 2-dose primary Moderna series and then receives a Moderna booster dose instead of an additional dose, then the Moderna booster dose was administered **in error**. Since this patient was supposed to receive an additional dose because of their immunocompromised status, but instead received a booster Moderna dose (which is half of the dosage that is used in the primary series), then this patient has received less than the intended dosage. There are two ways to approach this situation:

1. If this error was discovered **on the same clinic day**, then you may administer another half-volume Moderna dose (i.e., 0.25 mL) in the opposite arm and the two doses can together be counted as one full dose.
2. If this error was discovered later, and it is **now a different clinic day**, repeat a full dose of Moderna immediately (with no minimum interval from the previous 0.25 mL dose), preferably in the opposite arm.


The patient would then need to return in 5 months' time for their booster dose, once either of the above steps are taken.

Mask wearing update

People who reported always wearing a mask in indoor public settings were less likely to test positive for COVID-19 than people who didn't*

WEARING A MASK LOWERED THE ODDS OF TESTING POSITIVE

Among 534 participants reporting mask type[†]



bit.ly/MMWR7106

* Matched case-control study, 1,628 people, Feb 13–Dec 1, 2021

[†] Compared people with similar characteristics (e.g., vaccination)

[‡] Not statistically significant

MMWR

Testing Updates



Find a COVID-19 Test in New Mexico.

Knowing if you have COVID-19 can help you seek proper treatment and prevent you from spreading the virus to your family and community.

Get tested if:

- You have symptoms of COVID-19: cough, fever, shortness of breath, chills, repeated shaking with chills, muscle pain, headache, sore throat, congestion or runny nose, nausea or vomiting, diarrhea, and/or loss of taste or smell.
- You have been a close contact of someone who tested positive for COVID-19 (within 6 feet or less for more than 15 minutes).
- You are required to present a COVID-19 test to your employer, educational institution, or another entity.



To get started, please enter your information below:

ZIP CODE

[Find My Test](#)

Visit Your Local Pharmacy


At-home COVID-19 tests and PCR Laboratory COVID-19 tests are available at pharmacies throughout New Mexico at low or no cost with insurance.

- [CVS Health](#)
- [Walgreens](#)
- [Walmart](#)

Project ACT (Access Covid Tests - free home tests)

In partnership with Rockefeller Foundation

- Eligibility EXPANDED to ALL zip codes on Friday 2/4/22
- Free home tests
- Test mailed out by Amazon (but you don't need an account)
- 5 test kits per order
- 1 order per household
- Phase 1 will provide tests for 35,000 households (175,000 tests)
- [Project ACT | Home \(accesscovidtests.org\)](https://accesscovidtests.org)




Home Testing Program

PLAN:

- Standing order for home tests
- 11% of tests to Tribal Communities
- first 1 million tests distributed to high SVI zip codes
- next 1 million tests to be distributed to counties pro-rata
- Home test page: [Self Test Overview | NMDOH - Coronavirus Updates \(nmhealth.org\)](#)



New Mexico Department of Health COVID-19 Screening & Testing Sites



OPTIONAL REPORTING OF HOME TESTING

<https://covid-positive-home-test.doh.nm.gov/>



Self-Reporting Webform

English

Please report your positive home-based or self-administered COVID-19 test result to the New Mexico Department of Health here. You will need to give us personal details such as your name, date of birth, and address. You will also be asked a few additional questions about your health. Resource links are provided below. If you need help or have a question, call the COVID-19 hotline at 1-855-600-3453.

A home-based or self-administered COVID-19 test is a rapid test that you usually do yourself, and in your home. You should see for yourself the test result. Home/self COVID-19 tests always provide results in less than one hour, usually about 15 minutes.

These tests may have come from the postal service through www.COVIDtest.gov or were bought from pharmacies or online stores.

This portal is for home/self-kit COVID-19 POSITIVE test result reporting only. Do not report COVID-19 results from tests that were sent to a lab. Lab COVID tests include any swab collected at a medical clinic, CVS, Walgreens, other COVID testing center; or any test of your saliva sent to a lab for testing.

New Mexico Department of Health (NMDOH) will keep your information private.

Help stop the spread of COVID: Sign up for nmnotify.org

1. **Enable the app** on your smart phone: apple phone and google play
2. **Contact Exposures:** Once registered, you will receive text notifications if you have come into contact with someone who is positive for COVID.
3. **Report your positives:** If you are positive for COVID you can report your positivity on the app, and people you have come into close contact with will be notified they may have come into contact with an individual who is positive.



Therapeutics Update

[Information for Providers | NMDOH - Coronavirus Updates \(nmhealth.org\)](https://nmhealth.org/coronavirus/providers)



COVID-19 TREATMENTS



ORAL MEDICINES

PAXLOVID

WHO SHOULD USE IT:

People ages 12 or older, who are covid positive, who are not hospitalized, and who are at high risk for getting very sick.

HOW TO USE IT:

People using Paxlovid will need to take 3 pills, twice a day, for 5 days.

BENEFITS:

Paxlovid reduces the chance of hospitalization and death from COVID by 88% and can be taken at home.

MOLNUPIRAVIR

WHO SHOULD USE IT:

People ages 18 or older, who are covid positive, who are not hospitalized, and who are at high risk for getting very sick.

HOW TO USE IT:

People using Molnupiravir will need to take 4 pills, twice a day, for 5 days.

BENEFITS:

Molnupiravir reduces the chance of hospitalization and death from COVID by 30% and can be taken at home.



IV MEDICATIONS

REMDESIVIR

WHO SHOULD USE IT:

People ages 12 or older who are hospitalized with covid or not hospitalized but who are at high risk for getting very sick from covid.

HOW TO USE IT:

People using Remdesivir will need to get 1-2 hour infusions for 3 days. These infusions will be in a clinical setting such as a hospital.

BENEFITS:

Remdesivir reduces the chance of hospitalization and death from COVID by 87%.

SOTROVIMAB

WHO SHOULD USE IT:

People ages 12 or older, who are covid positive, who are not hospitalized, and who are at high risk for getting very sick.

HOW TO USE IT:

People using Sotrovimab will need to get a 30 minute infusion for 1 day. These infusions will be in a clinical setting such as a hospital.

BENEFITS:

Sotrovimab reduces the chance of hospitalization and death from COVID by 85%.

All COVID-19 treatments require a referral from a medical provider. If you do not have a medical provider, call the coronavirus hotline at: 1-855-600-3453



TRATAMIENTOS COVID-19



MEDICAMENTOS ORALES

PAXLOVID

QUIÉN DEBE USARLO:

Personas mayores de 12 años, que son positivas al COVID, que no están hospitalizadas y que tienen un alto riesgo de enfermarse gravemente.

CÓMO SE UTILIZA:

Las personas que tomen Paxlovid tendrán que tomar 3 pastillas dos veces al día, durante 5 días.

BENEFICIOS:

Paxlovid reduce la posibilidad de hospitalización y muerte por COVID en un 88% y puede tomarse en casa.

MOLNUPIRAVIR

QUIÉN DEBE USARLO:

Personas de 18 años o más, que son positivas al COVID, que no están hospitalizadas y que tienen un alto riesgo de enfermarse gravemente.

CÓMO SE UTILIZA:

Las personas que tomen Molnupiravir tendrán que tomar 4 pastillas, dos veces al día, por 5 días.

BENEFICIOS:

Molnupiravir reduce la posibilidad de hospitalización y muerte por COVID en un 30% y puede tomarse en casa.



MEDICAMENTOS INTRAVENOSOS

REMDESIVIR

QUIÉN DEBE USARLO:

Personas de 12 años o más que estén hospitalizadas con COVID o que no estén hospitalizadas pero que tengan un alto riesgo de enfermarse mucho por COVID.

CÓMO SE UTILIZA:

Las personas que utilicen Remdesivir deberán recibir infusiones de 1 a 2 horas durante 3 días. Estas infusiones se realizarán en un entorno clínico, como un hospital.

BENEFICIOS:

Remdesivir reduce la posibilidad de hospitalización y muerte por COVID en un 87%.

SOTROVIMAB

QUIÉN DEBE USARLO:

Personas mayores de 12 años, que son positivas al COVID, que no están hospitalizadas y que tienen un alto riesgo de enfermarse gravemente.

CÓMO SE UTILIZA:

Las personas que utilicen Sotrovimab deberán recibir una infusión de 30 minutos cada día. Estas infusiones se realizarán en un entorno clínico, como un hospital.



BENEFICIOS:

Sotrovimab reduce la posibilidad de hospitalización y muerte por COVID en un 85%.

Todos los tratamientos de COVID-19 requieren la remisión de un proveedor médico. Si no tiene un proveedor de servicios médicos, llame a la línea de atención de coronavirus al: 1-855-600-3453



COVID Oral Therapeutic Utilization



Update to OMASS Score

adapted from Mayo Clinic's published Monoclonal Antibody Screening Score (MASS)

RISK FACTOR	POINTS
Age 65 years and older	2
BMI 35 kg/m2 and higher	2
Diabetes mellitus	2
Chronic kidney disease	3
Cardiovascular disease in a patient 55 years and older	2
Chronic respiratory disease in a patient 55 years and older	3
Hypertension in a patient 55 years and older	1
Immunosuppressed and unlikely to have responded to vaccines (eg: CD20 inhibitors, BTK inhibitors, campath, recent CAR-T, organ transplant)	3
Pregnancy*, ⁷	4
BIPOC (Black, Indigenous, People of Color) status ⁸	1
Any other underlying medical condition associated with high risk for severe COVID-19 disease according to the CDC https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html	1

- **OMASS of 3** needed for prescription of Paxlovid and Sotrovimab
- **OMASS of 1** for Molnupiravir
- Prescription goes to:

Community, A Walgreens Pharmacy
933 San Mateo Blvd NE Suite 501,
Albuquerque, NM 87108

Phone: 505-313-8080
Fax: 505-313-8082

**Molnupiravir is not recommended for use in pregnancy.*

DOH Contact Information for Providers

CONTACT INFO	DESCRIPTION
COVID.Vaccines@state.nm.us	COVID-19 Vaccine Record requests; Provider COVID-19 Vaccine Order status; NMSIIS assistance.
COVID.Therapeutics@state.nm.us	Provider questions regarding COVID oral therapeutics (Molnupiravir and Paxlovid); COVID PrEP (Evusheld); mAB; or Remdesivir
COVIDData.compliant@state.nm.us	COVID-19 vaccine storage and handling questions, temperature log and onboarding Vaccine Plan submissions.
COVID.testing-doh@state.nm.us	For Provider questions on testing and test supplies

DOH Contact Information for Patients

CONTACT INFO	DESCRIPTION
COVID-19 Hotline: 1-855-600-3453	Users who have questions or would like support with vaccine registration and testing
ALTSD assistance: 1-800-432-2080	For seniors and those with disabilities who need support with vaccine registration and scheduling.
1-833-551-0518	For non-health related COVID-19 questions



**THANK
YOU!**